Vaccines and vaccination strategies against human cutaneous leishmaniasis.
One might think that the development of a vaccine against cutaneous leishmaniasis would be relatively straightforward because the type of immune response required for protection is known and natural immunity occurs following recovery from primary infection. However, there is as yet no effective vaccine against the disease in humans. Although vaccination in murine studies has yielded promising results, these vaccines have failed miserably when tested in primates or humans. The reasons behind these failures are unknown and remain a major hurdle for vaccine design and development against cutaneous leishmaniasis. In contrast, recovery from natural, deliberate or experimental infections results in development of long-lasting immunity to re-infection. This so called infection-induced resistance is the strongest anti-Leishmania immunity known. Here, we briefly review the different approaches to vaccination against cutaneous leishmaniasis and argue that vaccines composed of genetically modified (attenuated) parasites, which induce immunity akin to infection-induced resistance, may provide best protection against cutaneous leishmaniasis in humans.
Okwor
Ifeoma
I
Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, CA.
Uzonna
Jude
J
D000818:Animals; D006801:Humans; D007891:Leishmania / Q000235:genetics / Q000276:immunology; D054332:Leishmaniasis Vaccines / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D051379:Mice; D011323:Primates; D014611:Vaccination / Q000379:methods*
D054332:Leishmaniasis Vaccines